Stock Update: Amgen Inc (NASDAQ:AMGN) – FDA panel backs Amgen’s cholesterol drug for high-risk patients

[Reuters] – An advisory panel to the U.S. Food and Drug Administration recommended approval of Amgen Inc’s cholesterol-lowering drug Repatha but said it should be only used in patients at high risk of . . . → Read More: Stock Update: Amgen Inc (NASDAQ:AMGN) – FDA panel backs Amgen’s cholesterol drug for high-risk patients Similar Articles: Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s Repatha effective; question is for which patients–FDA Market Update (NASDAQ:AMGN): Amgen cholesterol drug could get EU green light this week Stock Update (NASDAQ:AMGN): U.S. FDA approves Amgen heart failure drug